UMass Medical School’s MassBiologics has received an orphan drug designation from the U.S. Food and Drug Administration for MBL-HCV1, a monoclonal antibody developed to prevent the recurrence of hepatitis C virus in patients receiving a liver transplant.
“Anti-gal” technology developed at UMMS has been licensed to newly formed biopharmaceutical company Agalimmune Ltd. for the purpose of developing innovative immunotherapies for the treatment of solid tumor cancers.
Scientists at the UMMS and the Wellcome Trust Sanger Institute have discovered evidence that a widely used antifungal medicine increases susceptibility to flu infection in mice and cell cultures.
Using next generation sequencing and population genetic modeling, scientists at UMass Medical School and the Ecole Polytechnique Fédérale de Lausanne have found that cytomegalovirus evolves rapidly and dramatically in humans. These findings, published in PLoS Genetics, provide new genetic targets that could impede the evolution of CMV and prevent its spread.
A 3-year-old Mississippi child born with HIV and treated with a combination of antiviral drugs very early remains free of active infection 18 months after all treatment ceased, according to an updated case report in The New England Journal of Medicine. Katherine Luzuriaga, MD, is senior author on the report.
Jeanne B. Lawrence, PhD, who earlier this year showed that it was possible to shut down the extra copy of chromosome 21, told the Boston Globe that the discovery is already providing new insights about what exactly goes wrong within Down syndrome cells.
Katherine Luzuriaga, MD, professor of molecular medicine, pediatrics and medicine, has been named vice provost for clinical and translational research.
A recent discovery by UMass Medical School scientists may provide researchers with a new approach for studying and potentially treating Fragile X syndrome.